Evaluation of biliary toxicity in patients with hepatic artery infusion pumps.

Joseph Elijah Allison J SchepersJohn C KraussRachel L McDevitt

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

Biliary toxicity remains a significant and therapy-limiting consequence of FUDR administration. Rising ALP may be an early indicator of subsequent biliary toxicity. Future studies with more patients may identify risk factors that can facilitate risk mitigation strategies.

Keyphrases

risk factors
oxidative stress
end stage renal disease
newly diagnosed
ejection fraction
low dose
prognostic factors
stem cells
bone marrow
current status
patient reported outcomes
cell therapy